Characteristic | Treated patients N=124 | RNA-sequencing‒evaluable population n=93 | WES-evaluable population n=79 | |
Responder, n (%) | 54 (43.5) | 38 (40.9) | 32 (40.5) | |
Median PFS, months (95% CI) | 7.4 (5.3 to 10.1) | 7.4 (5.3 to 9.7) | 7.4 (5.0 to 11.5) | |
Mean age, years (SD) | 65.3 (7.8) | 65.8 (7.7) | 66.0 (7.4) | |
Histology, n (%) | ||||
Endometrioid adenocarcinoma | 67 (54.0) | 47 (50.5) | 38 (48.1) | |
Serous adenocarcinoma | 39 (31.5) | 30 (32.3) | 27 (34.2) | |
Clear cell adenocarcinoma | 6 (4.8) | 6 (6.5) | 4 (5.1) | |
Adenocarcinoma NOS | 1 (0.8) | 1 (1.1) | 1 (1.3) | |
Dedifferentiated/undifferentiated carcinoma | 1 (0.8) | 0 | 1 (1.3) | |
Other | 10 (8.1) | 9 (9.7) | 8 (10.1) | |
ECOG performance status, n (%) | ||||
0 | 62 (50.0) | 44 (47.3) | 38 (48.1) | |
1 | 62 (50.0) | 49 (52.7) | 41 (51.9) | |
MSI-H status, n (%) | ||||
MSI-H | 15 (12.1) | 10 (10.8) | 11 (13.9) | |
MSS | 106 (85.5) | 83 (89.2) | 68 (86.1) | |
Not available | 3 (2.4) | 0 | 0 | |
PD-L1 status, n (%) | ||||
Positive | 60 (48.4) | 50 (53.8) | 41 (51.9) | |
Negative | 52 (41.9) | 42 (45.2) | 38 (48.1) | |
Not available | 12 (9.7) | 1 (1.1) | 0 |
ECOG, Eastern Cooperative Oncology Group; MSI-H, microsatellite instability-high; MSS, microsatellite stable; NOS, not otherwise specified; PFS, progression-free survival; WES, whole-exome sequencing.